Literature DB >> 30206985

Structural and energetic understanding of novel natural inhibitors of Mycobacterium tuberculosis malate synthase.

Rohit Shukla1, Harish Shukla1, Timir Tripathi1.   

Abstract

Persistent infection by Mycobacterium tuberculosis requires the glyoxylate shunt. This is a bypass to the tricarboxylic acid cycle in which isocitrate lyase (ICL) and malate synthase (MS) catalyze the net incorporation of carbon during mycobacterial growth on acetate or fatty acids as the primary carbon source. To identify a potential antitubercular compound, we performed a structure-based screening of natural compounds from the ZINC database (n = 1 67 740) against the M tuberculosis MS (MtbMS) structure. The ligands were screened against MtbMS, and 354 ligands were found to have better docking score. These compounds were assessed for Lipinski and absorption, distribution, metabolism, excretion, and toxicity prediction where 15 compounds were found to fit well for redocking studies. After refinement by molecular docking and drug-likeness analysis, four potential inhibitors (ZINC1483899, ZINC1754310, ZINC2269664, and ZINC15729522) were identified. These four ligands with phenyl-diketo acid were further subjected to molecular dynamics simulation to compare the dynamics and stability of the protein structure after ligand binding. The binding energy analysis was calculated to determine the intermolecular interactions. Our results suggested that the four compounds had a binding free energy of -201.96, -242.02, -187.03, and -169.02 kJ·mol-1 , for compounds with IDs ZINC1483899, ZINC1754310, ZINC2269664, and ZINC15729522, respectively. We concluded that two compounds (ZINC1483899 and ZINC1754310) displayed considerable structural and pharmacological properties and could be probable drug candidates to fight against M tuberculosis parasites.
© 2018 Wiley Periodicals, Inc.

Entities:  

Keywords:  Mycobacterium tuberculosis; binding energy; drug target; malate synthase (MS); molecular docking; molecular dynamic simulation; natural compounds; virtual screening

Year:  2018        PMID: 30206985     DOI: 10.1002/jcb.27538

Source DB:  PubMed          Journal:  J Cell Biochem        ISSN: 0730-2312            Impact factor:   4.429


  3 in total

1.  Identification of lead molecules against potential drug target protein MAPK4 from L. donovani: An in-silico approach using docking, molecular dynamics and binding free energy calculation.

Authors:  Shweta Raj; Santanu Sasidharan; Vikash Kumar Dubey; Prakash Saudagar
Journal:  PLoS One       Date:  2019-08-19       Impact factor: 3.240

2.  Targeting the nsp2 Cysteine Protease of Chikungunya Virus Using FDA Approved Library and Selected Cysteine Protease Inhibitors.

Authors:  Prateek Kumar; Deepak Kumar; Rajanish Giri
Journal:  Pathogens       Date:  2019-08-15

3.  High-throughput screening of natural compounds and inhibition of a major therapeutic target HsGSK-3β for Alzheimer's disease using computational approaches.

Authors:  Rohit Shukla; Tiratha Raj Singh
Journal:  J Genet Eng Biotechnol       Date:  2021-05-04
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.